Inhalation Sciences AB (ISAB) has received an order worth over SEK 914,000 (€81,200) for an Inhalation Research Service project from a new US customer developing targeted antiviral therapies. In this first project they have chosen to use the DissolvIt module to carry out dissolution testing, due to its exceptional accuracy which can reduce risk and attrition in later drug development. ISAB has received an order from a new customer, a cutting-edge US pharmaceutical company developing novel antiviral therapies to treat a range of viral diseases from influenza to COVID-19.

Initially the new customer will carry out in vitro dissolution testing using DissolvIt, ISAB's leading in vitro dissolution and absorption testing module.